AI Engines For more Details: Perplexity Kagi Labs You
Chemical Structure: Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride belongs to the class of isoquinoline compounds, which are aromatic heterocyclic organic compounds. Its chemical structure includes an isoquinoline core with two methoxy (CH3O) groups and a methyl (CH3) group, along with a tetrahydro (four-carbon) moiety. The hydrochloride salt form indicates that it is a salt formed by the reaction of the compound with hydrochloric acid.
Pharmacological Potential: Isoquinoline derivatives have been investigated for various pharmacological activities, including anticancer, antimicrobial, anti-inflammatory, and neuroprotective properties. However, without specific information about the biological activity and mechanism of action of this particular compound, its potential health impacts on medical conditions cannot be definitively determined.
Research and Development: Isoquinoline derivatives have been studied in medicinal chemistry and drug discovery programs as potential lead compounds for the development of new therapeutic agents. Researchers may investigate their structure-activity relationships, pharmacokinetics, and pharmacodynamics to identify compounds with desired biological activities and therapeutic profiles.
Safety Considerations: As with any chemical compound, safety considerations are paramount, especially when considering its potential use in medical applications. Toxicity studies and risk assessments would be necessary to evaluate the safety profile of isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride, including its potential for adverse effects, cytotoxicity, genotoxicity, and other safety concerns.
Regulatory Status: The regulatory status of isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride would depend on its intended use, formulation, and jurisdiction-specific regulations. Before any medical application, it would need to undergo rigorous testing and evaluation according to regulatory guidelines established by health authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Roseburia | genus | Decreases | 👪 Source Study | |
| Bacteroides | genus | Decreases | 👪 Source Study | |
| Bifidobacterium | genus | Decreases | 👪 Source Study | |
| Collinsella | genus | Decreases | 👪 Source Study | proinflammatory |
| Mediterraneibacter | genus | Decreases | 👪 Source Study | |
| Veillonella | genus | Decreases | 👪 Source Study | |
| [Ruminococcus] torques | species | Decreases | 📓 Source Study | |
| Bacteroides caccae | species | Decreases | 📓 Source Study | |
| Collinsella aerofaciens | species | Decreases | 📓 Source Study | |
| Bacteroides xylanisolvens | species | Decreases | 📓 Source Study | |
| Roseburia intestinalis | species | Decreases | 📓 Source Study | |
| Veillonella parvula | species | Decreases | 📓 Source Study | |
| Roseburia hominis | species | Decreases | 📓 Source Study | |
| Bifidobacterium adolescentis | species | Decreases | 📓 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.9 | -2 |
| ADHD | 1.2 | 0.3 | 3 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.3 | 1 |
| Allergies | 0.7 | 0.9 | -0.29 |
| Allergy to milk products | 0.6 | 0.6 | 0 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 0.9 | 2.4 | -1.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 1.2 | 0.3 | 3 |
| Anorexia Nervosa | 0.3 | 0.8 | -1.67 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 1.4 | 1.5 | -0.07 |
| Atherosclerosis | 0.9 | 0.7 | 0.29 |
| Atrial fibrillation | 0.9 | 0.6 | 0.5 |
| Autism | 2.4 | 1.5 | 0.6 |
| Autoimmune Disease | 0.3 | 0.8 | -1.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.3 | 0.8 | -1.67 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Cancer (General) | 0.3 | 0.2 | 0.5 |
| Carcinoma | 0.9 | 0.9 | 0 |
| Celiac Disease | 0.7 | 0.9 | -0.29 |
| Cerebral Palsy | 0.9 | 0.8 | 0.13 |
| Chronic Fatigue Syndrome | 0.9 | 0.9 | 0 |
| Chronic Kidney Disease | 1.7 | 1.5 | 0.13 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 1.4 | 0.8 | 0.75 |
| Colorectal Cancer | 2.4 | 1.4 | 0.71 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.3 | 1.1 | -2.67 |
| COVID-19 | 1 | 1.7 | -0.7 |
| Crohn's Disease | 1.7 | 1.4 | 0.21 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.2 | -1.2 | |
| deep vein thrombosis | 0.5 | 0.8 | -0.6 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 1.6 | 2 | -0.25 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 0.6 | 0.8 | -0.33 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.9 | 0.6 | 0.5 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 0.8 | 0.6 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 1.9 | -1.71 |
| gallstone disease (gsd) | 0.3 | 0.8 | -1.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.3 | 1.1 | -2.67 |
| Gout | 0.5 | 0.5 | |
| Graves' disease | 1.2 | 1.7 | -0.42 |
| Gulf War Syndrome | 0.3 | -0.3 | |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 2.1 | 1.2 | 0.75 |
| Heart Failure | 0.3 | 0.8 | -1.67 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | 0 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 0.1 | 0.6 | -5 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.5 | 1.2 | 0.25 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.6 | 0.3 | 1 |
| IgA nephropathy (IgAN) | 0.3 | 1.2 | -3 |
| Inflammatory Bowel Disease | 1.2 | 1.7 | -0.42 |
| Insomnia | 0.6 | 1.1 | -0.83 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.6 | -1 |
| Irritable Bowel Syndrome | 2.4 | 1.7 | 0.41 |
| ischemic stroke | 0.9 | 0.8 | 0.13 |
| Liver Cirrhosis | 1.5 | 1.4 | 0.07 |
| Long COVID | 1.3 | 1.6 | -0.23 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.1 | 0.1 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.6 | -0.6 | |
| ME/CFS without IBS | 0.6 | -0.6 | |
| Menopause | 0 | 0.5 | 0 |
| Metabolic Syndrome | 1.7 | 1.5 | 0.13 |
| Mood Disorders | 1.7 | 1.8 | -0.06 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 0.4 | 1.1 | -1.75 |
| Multiple system atrophy (MSA) | 0.1 | 0.3 | -2 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.9 | -0.9 | |
| Neuropathy (all types) | 0.7 | -0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 1.2 | -0.09 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.6 | 0.5 |
| Obesity | 2.4 | 1.5 | 0.6 |
| obsessive-compulsive disorder | 0.6 | 1.2 | -1 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 1.1 | 0.3 | 2.67 |
| Parkinson's Disease | 2.2 | 1.5 | 0.47 |
| Polycystic ovary syndrome | 1.1 | 1.1 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.6 | 0.6 | |
| Psoriasis | 0.7 | 0.8 | -0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 1.7 | -0.13 |
| Rosacea | 0.9 | 0.8 | 0.13 |
| Schizophrenia | 1.3 | 1.4 | -0.08 |
| Sjögren syndrome | 0.4 | 0.6 | -0.5 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.1 | 1.4 | -0.27 |
| Systemic Lupus Erythematosus | 0.6 | 0.8 | -0.33 |
| Tic Disorder | 0.6 | -0.6 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.6 | 1.2 | -1 |
| Type 2 Diabetes | 1.7 | 1.6 | 0.06 |
| Ulcerative colitis | 0.9 | 1.2 | -0.33 |
| Unhealthy Ageing | 1.2 | 0.8 | 0.5 |
| Vitiligo | 0.6 | 0.3 | 1 |
